GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Abeona Therapeutics Inc. (ABEO) [hlAlert]

Rating:
Speculative Buy
ACCP
up 51.61 %

Access Pharma (ACCP) rated Speculative Buy with price target $8 by Dawson James

Posted on: Monday,  Jun 16, 2008  8:25 AM ET by Dawson James

Dawson James rated Speculative Buy Abeona Therapeutics Inc. (NASDAQ: ABEO) on 06/16/2008, when the stock price was $3.10.
Since then, Abeona Therapeutics Inc. has gained 51.61% as of 12/16/2015's recent price of $4.70.
If you would have followed this Dawson James's recommendation on ABEO, you would have gained 51.61% of your investment in 2739 days.

Access Pharmaceuticals, Inc. (Access) is a biopharmaceutical company focused on developing products based upon its nanopolymer chemistry technologies and other drug delivery technologies. As of December 31, 2008, the Company has one approved product, one product at Phase III of clinical development, four products in Phase II of clinical development, and four products in pre-clinical development. On January 4, 2008, the Company acquired Somanta Pharmaceuticals, Inc. On February 25, 2009, Access acquired MacroChem Corporation.

Dawson James Securities is a full service investment firm with deep expertise in healthcare, biotechnology and technology with a staff of over 50 investment professionals ensures our clients stay ahead of the constant changes in the healthcare capital markets. From our widely-respected institutional research, investment banking and high net worth services to our personalized attention for individual accounts, we provide quality service for our clients. We take pride in the quality and depth of our professionals and encourage you to contact us so we can begin serving your financial needs today.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/16/2008 8:25 AM Buy
None
3.10 8.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy